HC Deb 30 November 1995 vol 267 c863W
Mr. Heppell

To ask the Secretary of State for Health (1) if he will provide extra funds to all hospital trusts to cover the extra cost of recombinant factor 8 products, incurred as a result of the imposition of value added tax on these products. [3134]

(2) what measure he is taking to ensure that hospital trusts buy and continue to buy the new recombinant factor 8 products in the wake of the imposition of value added tax on these products. [3131]

Mr. Horam

It is for clinicians to decide what products are used in the light of available resources and the needs of individual patients. Factor 8 derived from human plasma is used for the majority of patients and is exempt from value added tax.

Mr. Heppell

To ask the Secretary of State for Health what representations has he made to the Chancellor of the Exchequer regarding his decision to impose value added tax on recombinant factor 8 products. [3132]

Mr. Horam

The question of whether value added tax is chargeable on factor 8 products turns on whether they are derived from human blood. My Department has provided technical advice to HM Customs and Excise on that issue.

Back to